CTOs on the Move

United Therapeutics

www.unither.com

 
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. We currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! Our employees can be found collaborating across the United States, Europe and Asia. As a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases.
  • Number of Employees: 250-1000
  • Annual Revenue: $500M-1 Billion
  • www.unither.com
  • 1040 Spring Street
    Silver Spring, MD USA 20910
  • Phone: 877.864.8437

Executives

Name Title Contact Details
Shola Oyewole
Vice President of Digital Innovation Profile
Vicky Ames
Director, Information Security, Risk and Compliance Profile
Jeffrey Kase
Vice President and Chief Information Officer Profile

Similar Companies

Total Environmental Service Technologies Inc

Total Environmental Service Technologies Inc is a Peru, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Jounce Therapeutics

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within the human tumor microenvironment to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce is developing two clinical-stage programs as well as advancing and building out its broad and wholly-owned discovery pipeline of immuno-oncology targets, including those expressed on T-regulatory cells, macrophages and stromal cells. Jounce`s lead product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS and is currently being assessed in a Phase 2 clinical trial. JTX-4014 is a PD-1 inhibitor intended for use in combination with future pipeline products, and Jounce has completed enrollment in the JTX-4014 Phase 1 clinical trial. In addition, Jounce has exclusively licensed worldwide rights to JTX-8064, a LILRB2 receptor antagonist, to Celgene. For more information, please visit www.jouncetx.com. We have many career opportunities at Jounce and are looking for exceptional individuals who share our passion and perseverance for developing highly durable cancer immunotherapies that can dramatically impact and improve patients` lives.

cell signaling technology inc

cell signaling technology inc is a Danvers, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bioimaging At Cool Springs

Bioimaging At Cool Springs is a Franklin, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

New Century Imaging

New Century Imaging is a Oradell, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.